You are right, Anne-Marie, that androgens are needed for growth.  The people at NIH, I’m sure, will agree with you.  That is the whole theory behind this study....not to LOWER androgen production, but to allow them to go HIGHER, so as to promote better growth.  I think you misunderstand what the androgen blocker is supposed to achieve. 

 

 

***************************************************************************************************************

 

 

Flutamide, Testolactone, and Reduced Hydrocortisone Dose Maintain Normal Growth Velocity and Bone Maturation Despite Elevated Androgen Levels in Children with Congenital Adrenal Hyperplasia

 

Deborah P. Merke¹, Margaret F. Keil, Janet V. Jones¹, Jeremy Fields, Suvimol Hill and Gordon B. Cutler, Jr.²

Warren Grant Magnuson Clinical Center (D.P.M., S.H.), Developmental Endocrinology Branch (D.P.M., M.F.K., J.V.J., J.F., G.B.C.), National Institute of Child Health and Human Development, and Diagnostic Radiology Department (S.H.), National Institutes of Health, Bethesda, Maryland 20892

Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone. Twenty-eight children have completed 2 yr of follow-up in a subsequent long term randomized parallel study comparing these two treatment regimens. During 2 yr of therapy, compared to children receiving hydrocortisone, and fludrocortisone treatment, children receiving flutamide, testolactone, reduced hydrocortisone dose (average of 8.7 ± 0.6 mg/m²·day), and fludrocortisone had significantly (P 0.05) higher plasma 17-hydroxyprogesterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone levels. Despite elevated androgen levels, children receiving the new treatment regimen had normal linear growth rate (at 2 yr, 0.1 ± 0.5 SD units), and bone maturation (at 2 yr, 0.7 ± 0.3 yr bone age/yr chronological age). No significant adverse effects were observed after 2 yr. We conclude that the regimen of flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone provides effective control of congenital adrenal hyperplasia with reduced risk of glucocorticoid excess. A long term study of this new regimen is ongoing.